GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) — Arcellx today announced that the first patient has been dosed with its engineered T cell therapy utilizing a novel deimmunized synthetic binding domain in the treatment of patients with relapsed and refractory multiple myeloma. This first-in-human Phase 1 trial is the first in a series of clinical trials planned for efficient, stepwise development of the Arcellx ARC-T + sparX cell therapy platform, with BCMA as an initial target.
Judy Costello is the Managing Director of Economic Development for BioHealth Innovation, Inc. (BHI). A longtime supporter of the region’s entrepreneur and start-up communities, Judy Costello joined BioHealth Innovation in August 2017. Prior to that she served as Director of the Maryland Department of Commerce’s Office of BioHealth and Life Sciences and Deputy Director of the department’s BioMaryland Center. She previously worked for fifteen years for the Business Alliance organizing venture pitch forums, entrepreneur bootcamps, tech transfer showcases, educational seminars, and other programs connecting entrepreneurs, faculty innovators, students, and industry leaders in Maryland, DC and Virginia with each other and with those providing funding and other resources to young companies.
If you have been in fundraising mode anytime in the past 2-3 years and have gotten any term sheets with terms that were either outrageous or draconian, we want to hear from you. BHI Entrepreneur-in-Residence, Ethel Rubin is working on a future blog post and would like to hear from you. Email here at erubin@biohealthinnovation.org and share your term sheet stories today. Any information shared will be de-identified before adding to her post and you name/company will be kept confidential.
By Ethel Rubin
Opportunities abound for every investor looking for deal flow. Conversely, there have never been so many opportunities for entrepreneurs to pitch, network and mingle with investors. No matter what space you are in – fintech, biotech, edtech, cleantech, medtech – the world of investor showcases is exploding. Nevertheless, whatever the stage of your technology, there is nothing like a “warm” introduction and a few surefire ways of getting investors to take a look at you:
Most companies would admit that they miss more often than they hit when it comes to talent.
McKinsey & Company recently cited three rather stunning stats about talent: (1) 82% of Fortune 500 companies don’t believe they recruit highly talented people; (2) Of companies that do believe they recruit great talent, only 7% believe they can retain it; (3) and only 23% of managers and senior executives that deal with talent-related issues believe their current strategies actually work.
WASHINGTON (February 19) – Today, a diverse group of research and scientific organizations, as well as those directly involved in commercializing new products, launched Bayh-Dole 40, a coalition that will celebrate and protect the University and Small Business Patent Procedures Act of 1980, better known as the “Bayh-Dole Act.”
The Bayh-Dole Act has empowered universities, small businesses, and nonprofits that have received federal grants to retain ownership of any patented inventions — and license those patents to private firms, who then turn promising ideas into real-life products that improve peoples’ lives. Thanks to Bayh-Dole, the public and private sectors have worked together to translate basic scientific research into life-saving drugs and medical devices, internet and GPS technologies, rechargeable lithium-ion batteries, and countless other innovations.
Date: 1/22/2020 Expressions of Interest are due no later than 4:59pm EST on Monday, March 2, 2020. CAPCaT Contact: Mary Dubuque Email: mary.dubuque@umassmed.edu
Funding Opportunity The Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Disorders (U54HL143541) announces the 2020 solicitation of grant applications focused on developing, adapting, or validating point of care technologies that can be rapidly applied to heart, lung, blood, or sleep disorders, with additional interest in projects that incorporate complementary and integrative health approaches. We plan, based on the receipt of meritorious applications, to fund up to six awards of up to $100,000 over 12 months, with one or more award(s) focused on complementary and integrative health.
Less than 4% of money raised for cancer research targets pediatric cancers, but a D.C.-area charity that’s devoting resources to benefit young cancer victims is sponsoring trials at Children’s National Hospital.
Clinical trials underway for about a year are turning patients’ own immune system cells into an army of soldiers to attack their brain cancer tumors.
“We’re all really excited,” said Dr. Eugene Hwang, associate division chief of oncology at Children’s National Hospital. “The biggest problem would have been if we ran into a big side effect or toxicity signal, and we have not.”
WASHINGTON (February 19) – Today, a diverse group of research and scientific organizations, as well as those directly involved in commercializing new products, launched Bayh-Dole 40, a coalition that will celebrate and protect the University and Small Business Patent Procedures Act of 1980, better known as the “Bayh-Dole Act.”
The Bayh-Dole Act has empowered universities, small businesses, and nonprofits that have received federal grants to retain ownership of any patented inventions — and license those patents to private firms, who then turn promising ideas into real-life products that improve peoples’ lives.
Image: https://www.ipwatchdog.com
The BioHealth Capital Region (BHCR) is evolving quickly and it can be tough to keep pace with the latest news emerging from the host of biotech, medical device and cell, and gene therapy companies in the area. BioBuzz, when combined with some strategic social media follows, can help you stay on top of the latest developments, news and thought leadership coming out of the BHCR.
Image: https://biobuzz-io.cdn.ampproject.org
